Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared Bishal Gyawali’s, Associate Professor at Queen’s University, post on X, adding:
“Wonderful to meet Bishal Gyawali at JAMA Onc Reception.
We won’t always agree, but we’re aligned where it matters: helping patients and pushing oncology forward. All roads lead to Rome – and ours lead to outdoing cancer. Congratulations on the promotion to full Professor.”
Quoting Bishal Gyawali’s post:
“Lovely to run into Vivek Subbiah at the JAMA reception in Chicago today during ASCO26. Although Vivek and I may disagree on a few philosophical points (and we have published against each others’ viewpoints a couple of times), he is a great example of how that can stay separate from personal friendship. Indeed, getting my OncoDaily.
Challenging the Status Quo award from Vivek last year remains a major highlight of my career.”
Other articles featuring Vivek Subbiah and Bishal Gyawali on OncoDaily.